Search Results - Steven Simoens

Refine Results
  1. 1

    How to assess the value of medicines? by Steven Simoens

    Published in Frontiers in Pharmacology (2010-09-01)
    Get full text
    Article


  2. 2

    Assessment of methodological quality of economic evaluations in belgian drug reimbursement applications. by Steven Simoens

    Published in PLoS ONE (2013-01-01)
    Get full text
    Article


  3. 3

    Emerging Insights into European Markets of Biologics, Including Biosimilars by Steven Simoens, Isabelle Huys

    Published in Pharmaceuticals (2022-05-01)
    Get full text
    Article


  4. 4

    Generic Medicine Pricing Policies in Europe: Current Status and Impact by Pieter Dylst, Steven Simoens

    Published in Pharmaceuticals (2010-03-01)
    Get full text
    Article


  5. 5

    Tendering and biosimilars: what role for value-added services? by Steven Simoens, Raymond Cheung

    Published in Journal of Market Access & Health Policy (2020-01-01)
    Get full text
    Article


  6. 6

    Guidance for Demonstrating the Societal Value of new Antibiotics by Steven Simoens, Isabel Spriet, Isabel Spriet

    Published in Frontiers in Pharmacology (2021-02-01)
    Get full text
    Article


  7. 7

    Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study by Steven Simoens, Arnold G. Vulto, Pieter Dylst

    Published in Pharmaceuticals (2021-05-01)
    Get full text
    Article


  8. 8

    What role for real-world evidence in market access of biosimilars? by Steven Simoens, Catherine M. Lockhart, Delphine F. Courmier

    Published in Frontiers in Pharmacology (2025-02-01)
    Get full text
    Article


  9. 9

    A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe by Khadidja Abdallah, Kris De Boeck, Marc Dooms, Steven Simoens

    Published in Frontiers in Pharmacology (2021-11-01)
    Get full text
    Article


  10. 10

    How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries by Alessandra Blonda, Yvonne Denier, Isabelle Huys, Pawel Kawalec, Steven Simoens

    Published in Frontiers in Pharmacology (2022-07-01)
    Get full text
    Article


  11. 11

    Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer by Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes, Steven Simoens

    Published in Frontiers in Pharmacology (2017-09-01)
    Get full text
    Article


  12. 12

    Economic evaluation of biosimilars for reimbursement purposes – what, when, how? by Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto, Steven Simoens

    Published in Journal of Market Access & Health Policy (2020-01-01)
    Get full text
    Article


  13. 13

    Informing Patients about Biosimilar Medicines: The Role of European Patient Associations by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys

    Published in Pharmaceuticals (2021-02-01)
    Get full text
    Article


  14. 14

    The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys

    Published in Health Research Policy and Systems (2023-07-01)
    Get full text
    Article


  15. 15

    Cost analysis of a medication dispensing service in community pharmacy in Brazil by Thaissa Costa Cardoso, Steven Simoens, Alexander Itria, Nathalie de Lourdes Souza Dewulf

    Get full text
    Article


  16. 16

    Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study by Khadidja Abdallah, Kathleen Claes, Isabelle Huys, Lennert Follon, Charlotte Calis, Steven Simoens

    Published in Orphanet Journal of Rare Diseases (2022-12-01)
    Get full text
    Article


  17. 17

    Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices by Liese Barbier, Steven Simoens, Caroline Soontjens, Barbara Claus, Arnold G. Vulto, Isabelle Huys

    Published in Pharmaceuticals (2021-05-01)
    Get full text
    Article


  18. 18

    Not one, but many: developing a multi-indication pricing model for medicines in Belgium by Ingrid Maes, Eline Kok, Pieter-Jan De Torck, Jorge Mestre-Ferrandiz, Steven Simoens

    Published in Frontiers in Pharmacology (2023-09-01)
    Get full text
    Article


  19. 19

    Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies by Sissel Michelsen, Sissel Michelsen, Salma Nachi, Walter Van Dyck, Steven Simoens, Isabelle Huys

    Published in Frontiers in Pharmacology (2020-12-01)
    Get full text
    Article


  20. 20

    An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain by Teresa Barcina Lacosta, Arnold G. Vulto, Arnold G. Vulto, Isabelle Huys, Steven Simoens

    Published in Frontiers in Medicine (2023-01-01)
    Get full text
    Article


Search Tools: